In recent years the utilization of risk-sharing mechanisms – also known as managed entry agreements (MEAs) – has become increasingly common in healthcare systems around the world. Britain, Italy, Canada, and Korea are prominent examples. These arrangements have been welcomed by both the pharmaceutical industry and national healthcare administrations as a means of accommodating innovative…

Transforming Taiwan into a regional biomedical hub will require some creativity. Taiwan’s biomedicine industry has many of the ingredients for success. The island has strong scientific talent, rich clinical-trial experience, abundant capital, a treasure trove of medical data (from the National Health Insurance system), information-technology expertise, and strong intellectual property rights protection bolstered by the…

Finding new treatments for difficult to cure diseases Devoted to improving local education and medical care Although Chicago-based AbbVie was founded only five years ago, its performance in delivering new drugs for hard-to-treat diseases and its dedication to improving local medical services and education have quickly received global attention. “Our goal is to provide groundbreaking…

The Taiwan government deserves congratulations for its recent enactment of landmark legislation establishing a Patent Linkage system for pharmaceutical products, a mechanism designed to prevent infringing drugs from being licensed while an original medication still holds a valid patent in this market. Credit goes both to the executive branch agencies that ushered through this initiative…

Strengthening protection of intellectual property rights (IPR) is crucial to attracting investment in Taiwan’s pharmaceutical sector. In order to better protect IPR for innovative products, the Pharmaceutical Committee of the American Chamber of Commerce in Taipei recommends completing the legislative process for Patent Linkage and Data Exclusivity. Patent Linkage prevents regulatory authorization of generic medicines…

“Robust intellectual property (IP) protection is vital for biopharmaceutical innovation,” stresses a recently released report from Geneva Network, a UK-based public policy research and advocacy organization specializing in international intellectual property, health, and trade issues. The report – written by Geneva Network researcher Jack Ellis, a former Asia-Pacific editor of Intellectual Asset Management magazine –…